Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

Sep 26 2019

• By Ian Haydock

ApproveOnKeyboard_1200x675 — Roxadustat Among Key New Japan Approvals • Source: Shutterstock

Related Content

Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data

Oct 22 2018

Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally

Jul 24 2019

First Approval For AZ's Roxadustat With China Green Light

Dec 18 2018

Legal Challenge To First Japan Rituxan Biosimilar Dismissed

May 30 2019

Related Companies

Astellas Pharma, Inc.

FibroGen, Inc.

Akebia Therapeutics, Inc.

Japan Tobacco Inc.

Torii Pharmaceutical Co. Ltd.

GSK plc

Kyowa Kirin Co., Ltd.

AstraZeneca PLC

Takeda Pharmaceutical Co. Ltd.

Meiji Seika Pharma Co., Ltd

H. Lundbeck A/S

Newron Pharmaceuticals S.p.A.

Eisai Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Ono Pharmaceutical Company, Ltd.

Les Laboratoires Servier

Chugai Pharmaceutical Co., Ltd.

Roche Holding AG

Mochida Pharmaceutical Co., Ltd.

Gedeon Richter Plc.

Eli Lilly and Company

JCR Pharmaceuticals Co., Ltd.

Amgen, Inc.

Kissei Pharmaceutical Co., Ltd

Pfizer Inc.

Novartis AG

Mitsubishi Tanabe Pharma Corporation

Ultragenyx Pharmaceutical Inc.

Additional Topics

Japan Asia Pacific Approvals Commercial Government Payers Blood & Coagulation Disorders Cancer Neurology BioPharmaceutical

More from Japan

More from Focus On Asia

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.